Symic, a San Francisco, CA-based clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), secured $25m in Series A-2 financing.
The round was led by Lilly Ventures with participation from all existing major investors, as well as several new investors.
The company, which has now raised over $43m in total, will use the funds to advance its pipeline, including its lead candidates SB-030 and SB-061.
Founded in 2012 and led by Ken Horne, Chief Executive Officer, Symic recently initiated the Phase 1/2 SHIELD clinical trial to evaluate the safety and efficacy of SB-030, a locally applied, single-use treatment for the reduction of acute inflammation resulting from the vascular injury following percutaneous transluminal angioplasty in patients with peripheral artery disease.
The company is also advancing its proprietary treatment SB-061 in osteoarthritis.